Browse by People

Collapse authors list.
Griffiths, Gareth O, FitzGerald, Richard, Jaki, Thomas, Corkhill, Andrea, Reynolds, Helen ORCID: 0000-0001-7443-4520, Ewings, Sean, Condie, Susannah, Tilt, Emma, Johnson, Lucy, Radford, Mike et al (show 27 more authors) , Simpson, Catherine, Saunders, Geoffrey, Yeats, Sara, Mozgunov, Pavel, Tansley-Hancock, Olana, Martin, Karen, Downs, Nichola, Eberhart, Izabela, Martin, Jonathan WB, Goncalves, Cristiana, Song, Anna, Fletcher, Tom, Byrne, Kelly, Lalloo, David G ORCID: 0000-0001-7680-2200, Owen, Andrew ORCID: 0000-0002-9819-7651, Jacobs, Michael, Walker, Lauren ORCID: 0000-0002-3827-4387, Lyon, Rebecca, Woods, Christie, Gibney, Jennifer, Chiong, Justin ORCID: 0000-0001-8063-6399, Chandiwana, Nomathemba, Jacob, Shevin, Lamorde, Mohammed, Orrell, Catherine, Pirmohamed, Munir ORCID: 0000-0002-7534-7266 and Khoo, Saye ORCID: 0000-0002-2769-0967 (2021) AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22 (1). 487-.

Collapse authors list.
Khoo, Saye H ORCID: 0000-0002-2769-0967, Fitzgerald, Richard, Fletcher, Thomas, Ewings, Sean, Jaki, Thomas, Lyon, Rebecca, Downs, Nichola, Walker, Lauren ORCID: 0000-0002-3827-4387, Tansley-Hancock, Olana, Greenhalf, William et al (show 28 more authors) , Woods, Christie, Reynolds, Helen ORCID: 0000-0001-7443-4520, Marwood, Ellice, Mozgunov, Pavel, Adams, Emily, Bullock, Katie ORCID: 0000-0002-5758-0179, Holman, Wayne, Bula, Marcin D, Gibney, Jennifer L, Saunders, Geoffrey, Corkhill, Andrea, Hale, Colin, Thorne, Kerensa, Chiong, Justin ORCID: 0000-0001-8063-6399, Condie, Susannah, Pertinez, Henry, Painter, Wendy, Wrixon, Emma, Johnson, Lucy, Yeats, Sara, Mallard, Kim, Radford, Mike, Fines, Keira, Shaw, Victoria ORCID: 0000-0002-0429-0186, Owen, Andrew ORCID: 0000-0002-9819-7651, Lalloo, David G ORCID: 0000-0001-7680-2200, Jacobs, Michael and Griffiths, Gareth (2021) Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76 (12). pp. 3286-3295.